No Prescription |
 |
 | ||
|
Neasyn SR Niaspan |
|
| ||
No Prescription » Prescription Drugs 11 » Neasyn SR Niaspan Niacin (nicotinic acid) is used to prevent and treat niacin deficiency (pellagra). Niacin deficiency may result from certain medical conditions (e.g. alcohol abuse malabsorption syndrome Hartnup disease) poor diet or long-term use of certain medications (e.g. isoniazid).Niacin deficiency can cause diarrhea confusion (dementia) tongue redness/swelling and peeling red skin. Niacin is also known as vitamin B3 one of the B-complex vitamins. Vitamins help to support the body's ability to make and break down natural compounds (metabolism) needed for good health. Buy Neasyn SR Niaspan and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Neasyn SR Niaspan: Product Type: Prescription Drugs 11 Neasyn SR (Niaspan Nialip Generic Nicotinic Acid) Neasyn SR (Niaspan Nialip Generic Nicotinic Acid) Niaspan Nialip Generic Nicotinic Acid 500mg Niaspan Nialip Generic Nicotinic Acid Neasyn SR
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
